PannonPharma Inc., the Stalwart Frontrunners of the
Added-value Pharma Industry O ers Generic Based
BREAKTHROUGH Therapy Against SARS-Cov-2 in COVID-19
and Control over Pandemic
Most Leading
Companies to
Mr JP Pallos
CEO
PannonPharma Inc.

Editor’s
Note
resources on complying with the physician’s prescribed
drugs? With the rising costs of healthcare services
globally, a greater percentage of customers’ out-of-pocket
spending goes into buying drugs prescribed by their
physicians. Surprisingly, in recent years, this spending has
far exceeded the overall medical spending, which is
concerning for the government, customers, and the
healthcare sector.
The scenario could be attributed to the pharmacy industry,
which spends millions of dollars in its drug-making
process. From conducting multiple drug-making and
clinical trials—to wasting a billion dollars on product
failure—until they reach a health-satisfactory innovation.
They consider themselves rightful for pricing their drugs to
the level they desire and repeat this process until it drains
the customers’ health and financial resources overall. It is
impactful for them in all existing forms.
For those who are poor, the idea of drug affordability has
gotten far out of their hands. Even the ones who, despite
being insured, are required to spend out of their pockets to
A Paradigm
Shift in the
Global Healthcare

fulfil additional drug expenses. In both cases, customers end
up denying the consumption of prescribed drugs due to
their inability to afford them.
But it doesn’t have to be the case. Instead of completely
denying it, they have an alternative of using generic drugs.
Generic drugs are pharma medicines that are not only cost-
effective but perform the same role that a branded drug
would do. They have the same dosage, kinetics, strengths,
quality, and intended usage. Approved by the FDA, generic
drugs are being promoted in the market at a faster pace
today.
“If generic drugs can provide us the same therapy that a
branded drug, then why not give it a try?” Hopeful about
cost savings, customers are starting to give it a thought.
Realizing the increasing preferences towards generic drugs,
we at Insights Care, through our latest edition, “10 Most
Leading Generic Pharma Companies to Watch in 2022,”
will be signifying the shift in the industry’s operations to
reach where customers are headed.
Haveaninsightfulread!
-Saloni Agarwal

C
O
N
T
E
N
TS PannonPharma Inc.
PannonPharma Inc., the Stalwart Frontrunners of the Added-value
Pharma Industry Offers Generic Based BREAKTHROUGH Therapy Against
SARS-Cov-2 in COVID-19 and Control over Pandemic
08

Articles
ARTICLES
16
Rus Biopharm
A One-Stop Solution for
Asthma and COPD
20
Interview with
Insights Care
28
Few Things in Life
are Certain –Greater
Automation is One of Them!
CXO
STADA Arzneimittel AG
Legacy of Care with
High-quality Pharmaceuticals
Interview with
Insights Care
32
24
By- Graeme Ladds

Co-designer Paul Belin
Art & Picture Editor Mrunalinee Deshmukh
Art & Design Head
Editor-in-Chief Pooja Bansal
Managing Editor Shrutika Khedekar
Senior Editor Anish Miller
Visualiser David King
Research Analyst Eric Smith
Sarah Wilson, John Smith, Alex Vincent
Business Development Executives
Amy Jones
Business Development Manager
Sales Executives Kelli, Bill, Anna
SME-SMO Executives Gemson
Digital Marketing Manager Alina Sege
Technical Consultants David, Robert
Technical Head Jacob Smile
Marketing Manager John Smith
Assistant Technical Head Amar Sawant
Assistant Digital Marketing Manager Renuka Kulkarni
Assisting Editors Saloni, Drishti
Sonia Raizada
Circulation Manager Tanaji Fartade
Copyright © 2022 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or
transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success.
Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Insights Care is powered by Insights Success Media and Technology Pvt. Ltd.
September, 2022
Follow us on : www.facebook.com/InsightsCare/ https://twitter.com/Insightscare
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin, OH 43017, United States
Phone - 302-319-9947
Email: info@insightscare.com
For Subscription: www.insightscare.com
Insights Success Media and Technology Pvt. Ltd.
Office No. 22, Rainbow Plaza, Shivar Chowk,
Pimple Saudagar, Pune, Maharashtra 411017
Phone - India: 7410033802, 74100058552
Email: info@insightscare.com
For Subscription: www.insightscare.com
sales@insightscare.com
Contact Us:

Brief
Featuring Person
Company
JAMP Pharma Corp.
jamppharma.ca
Sophie Jacques
Director of
Communica ons
JAMP Pharma Corp. is commi ed to suppor ng healthcare
professionals so that they may focus on what ma ers
most: the well-being of Canadians.
MJ Biopharm Pvt. Ltd.
mjgroup.co.in
Amol Shah
Managing Director
MJ Biopharm Pvt. Ltd. is a growing mul -na onal
conglomerate with a presence in Pharmaceu cals,
Biotechnological, Flavours, Fragrances, Agro Chemicals &
Speciality Chemicals Industries.
Srinivasu Topalli
Senior General Manager
Natco Pharma
natcopharma.co.in
Natco Pharma manufactures niche and complex pharma
products, making them accessible to all.
Orchid Chemicals &
Pharmaceu cals
orchidpharma.com
Mridul Dhanuka
Director
Orchid Chemicals & Pharmaceu cals is a ver cal integrated
company having a mul -therapeu c presence across
segments like an -infec ves, an -inflammatory, central
nervous system (CNS), cardio vascular segment (CVS),
nutraceu cals and other oral and sterile products.
PannonPharma Inc
pannonpharma.hu
Mr JP Pallos
CEO
PannonPharma Inc has been manufacturing
pharmaceu cals and performing related pharmaceu cal
research and development, as well as pharmaceu cal
analy cal, and quality development ac vi es.
Pharmathen S.A.
pharmathen.com
Dimitris Kadis
CEO
Pharmathen S.A. aims to provide Life Cycle Management
solu ons for branded pharma, as well as develop and
establish new technology pla orms, and provide op mized
pharmaceu cal products to pa ents.
Sushmita Tamang
Pharmax Pharmaceu cals is a business of manufacturing
and commercializing high quality, safe, efficacious, and
cost effec ve pharmaceu cal products that exceeds the
pa ents and customer expecta ons.
Pharmax Pharmaceu cals
Pharmax.ae
Graeme Ladds
CEO
PharSafar provides tailored solu ons to act as a complete
pharmacovigilance, cosmetovigilance and medical services
department.
PharSafar
pharsafer.com
Rhodes Pharmaceu cals L.P
rhodespharma.com
Vincent Mancinelli
President
Rhodes Pharmaceu cals L.P—with its R&D capabili es,
industry partnerships, broad customer base, and strong
rela onships with suppliers—offers reliable supply of
high-quality products at compe ve prices.
Rus Biopharm
rusbiopharm.ru
Satya Karm Punia
President
Rus Biopharm develops and implements innova ve
approaches in biopharmaceu cs, focusing on pa ents
suffering from severe socially significant diseases.
Stada Arzneimi el
stada.com
Peter Goldschmidt
CEO
Stada Arzneimi el is a leading manufacturer of high-quality
pharmaceu cals. With a long-standing heritage rooted in
pharmacies, we are perceived as a reliable and trustworthy
partner for more than 125 years.

Mr JP Pallos
CEO
PannonPharma Inc

PannonPharma Inc.
PannonPharma Inc., the Stalwart Frontrunners
of the Added-value Pharma Industry Offers
Generic Based BREAKTHROUGH Therapy Against
SARS-Cov-2 in COVID-19 and Control over Pandemic
PannonPharma's mission
is to develop new medicines, new
medical technologies, by inventing,
repurposing, repositioning generics to
generic+ pharmaceutical
products.
Cover Story

Back in the 1980s, a group of young research
fellows, medical doctors, bio-analysts formed a
research group. They were investigating the
metabolic changes of astronauts during their space flight,
and in parallel, started to study cholesterol metabolism of
patients with hepatobiliary disorders. They pioneered
instrumental chromatography, the HPLC, the revolutionary
separation science on this field. This research project was
supported by George Soros in the form of world class
scientific instrumentation.
This research work lead to discover the role of bile acids in
cholesterol metabolism and to understand its role in "high
cholesterol level associated diseases." Despite the hard
working, promising results, the golden age of "statins" as
pharmaceuticals, made it impossible to commercialize the
invention. But the knowledge they gained is not lost. High
cholesterol level is the major risk factor of sever Covid-19,
and mostly responsible for the coronavirus pandemic as
well.
Their early results just need to be reevaluated when the first
papers published about Cholesterol role in COVID-19,
which is a major key-risk factor and has a definitive role in
the pathogenesis and decourse of SARS-CoV-2 infection.
Cholesterol is the question of death or life, and offers new
treatment modalities for COVID-19 patients.
This research group and their work laid the foundation for
PannonPharma Inc. and among them was the company's
current CEO – J. P. Pallos.
PannonPharma Pharmaceutical Inc. is more an R&D-driven
generic plus pharma company than a large-scale
pharmaceutical manufacturer. PannonPharma's R&D team
continuously monitors the new treatment opportunities in
medicine and medical technologies related to challenges by
new infections and diseases. The innovations are based
mainly on repurposing its portfolio with well-established
use products.
PannonPharma is the only company so far, that offers ram
to the jab, a new solution to stop or alleviate the
coronavirus pandemic, where the barehanded jab is the
mandatory vaccination, which can strengthen by a ram,
which is the gastrointestinal (GI) SARS-Cov-2 virus
disinfection by the newly discovered virus structural
disrupter.
The company's new paradigm is a non-systemic treatment
to eradicate SARS-CoV-2 in the intestines, i.e. viral
disinfection of the GI tract, necessary to stop virus shedding
by symptomless virus carriers, as well. This new treatment
modality (patent application submitted) might be a life-
saving treatment of COVID-19 patients and ought to be the
subject of emergency market authorization by regulatory
bodies.
Non-systemic treatment is a mild medical intervention, as
drug does not enter into the circulatory system, have no
effect on vital organs, therefore side effects are rather lower
in frequency.
The active pharmaceutical ingredient (API) of this patented
antiviral therapy is the well known antimycotic drug
Nystatin, with forgotten, repurposed antiviral activity. By
inhibiting the nasty fungy species, mostly Candida
albicans, at the same time, Nystatin is capable to
denaturalize the coronaviruses and their possible mutants as
well, which are accounted as one of the major cytokine
storm inducers too. It can be used immediately, by
emergency use market authorizations. This is
PannonPharma's very last project, still open, for clinical
trials, one might be necessary afterwards. Investors are welcome!
Mission:
PannonPharma's mission is to develop new medicines, new
medical technologies, by inventing, repurposing,
repositioning generics to generic plus pharmaceutical
products, having active substances with well-documented
safety and beneficial effect in therapies.
PannonPharma's R&D team
continuously monitors the new
treatment opportunities in
medicine and medical technologies
related to challenges by new
infections and diseases.
10 Most Leading Generic Pharma Companies to Watch in 2022

Range of PannonPharma's Offerings
The full scope of PannonPharma's activities covers
manufacturing of generics and original medicines (EU
GMP), import and distribution medicinal products from
third countries, drug regulatory affairs, sales, scientific and
technical research and development, medicine analytics,
engineering, consulting. Its portfolio includes more than
seventy products: tablets, capsules, granules, solutions,
sterile solutions, ointments, injectable and powder mixtures.
PannonPharma Group of Companies is also a think-tank
that offers simple solutions for complex problems.
They develop products to meet the unmet needs in the
therapy of:
Ÿ Multi-resistant SA Staphylococcus aureus topical
treatment by primycin antibiotics,
Ÿ To stop coronavirus: the API for COVID-19, SARS-
CoV-2 virus eradication in:
Ø GI tract – disinfection agents and their
combinations,
Ø Nose – Nasal drops, spray by interferon,
Ø Eye – eye drop,
Ø Ear – ear drops,
Ø herbal substances for inhalation solution to
disinfect the respiratory system and lungs
Ÿ Free radical scavengers to treat oxidative stress diseases
in virus infections, and vaccinations
Ÿ Complex health food supplement to tune the immune
system up against viruses and vaccines
Ÿ Antiviral Cancer treatment by herbal substances
Ÿ Non-GMO superfood, virus-resistant and protein-rich
potato varieties
There are new technologies rising on the horizon.
Reconstruction surgeries need precisely manufactured
implants. PannonPharma's partnership company developed
the CT segmentation imaging technology, able to extract
precise anatomic profiles from noisy CT recordings, in a
very short period of time. They plan to add value by
manufacturing tailor-made bone and 3D tissue cultured
implants.
What makes PannonPharma Stand Out
PannonPharma claims to be the only company that may
contribute to stopping, alleviating the SARS-CoV-2
pandemic, by non-systemic viral disinfection of the GI
tract, repurposing cholesterol-binding Nystatin drug. Its
antiviral activity is a very robust one, destroys the envelop
structure of all coronaviruses and their mutants, too.

The ongoing pandemic shall be controlled applying two
principles of social defense: the first is vaccination of
masses, as a systemic treatment, as much as possible. The
second one must be a non-systemic treatment of GI
disinfection, eradication of the virus from the intestines.
This non-systemic treatment is also mandatory because the
infection in the GI tract may cause damage to the intestinal
barriers. This viral attack on vital organs via circulation
(viremia) may cause clinically severe or fatal conditions in
patients. The persistence of the virus in the GI tract may
lead to post-COVID symptoms and further re-infections.
Worldwide, there are generic 'me too' companies making
one-to-one copies of original drugs, and there are generic
plus innovation driven pharmaceutical companies, like
PannonPharma.
The company does repurposing for extension of
therapeutical indication of drugs, with well-known API or
added-value reformulation of well-known active
pharmaceuticals. These new treatment modalities might be
of high value.
The Cultivated Leader
From East to West, Mr J. P. Pallos was pioneering the
beautiful epoch where technology meets science.
He had the privilege to start his pharmaceutical industry
career at the famous innovation-driven company, Hewlett-
Packard Inc's Analytical Instruments Division, now called
Agilent, in 1987. Arriving from the East-Block, he was the
funny guy in the focus or interest of the whole company, the
first direct HP head-count employee from the communist
world. He got the task, to his carrier, from the President of
HP during their face-to-face short meeting in Vienna,
Austria.
In 1987, John A. Young advised Mr Pallos to conquer
Hungary for HP Analytics Instruments. He did that and
supplied the best instrumentation and technology from HP
Analytic Division to the pharma companies.
By far, separation sciences have played a major role in
medical, chemical, material disciplines over the past 50
years. No technology, no scientific progress is accountable
without chromatography, electrophoresis, technics, and
instrumentation. Progress was made by US-based
companies and they are leading the way.
Awards and Accolades
Mr J. P. Pallos was awarded the 'TOP 100 Hewlett-Packard
Employee Award'.
Mr J. P. Pallos is a member of the board of Europharm
SMC Association of Pharmaceutical Manufacturers of the
European Union.
The Pandemic Dictate
A SWOT analysis about the introduction of the pandemic
on the global pharma industry specifically, might better
explain the effect COVID-19 has had:
Strength – the pharma industry is one of the major role
players to have control of the pandemic.
Weakness – means all modalities of treatment shall be
carefully investigated. Vaccination, by itself, is not
satisfactory to stop the pandemic.
Opportunities – complex problems may require simple
solutions for a new paradigm.
Threats – monopolies in the supply of life-saving drugs
resulting in weakness in any state defense.
From the point of view of the industry, COVID-19 acts as a
kind of catalyst: it accelerates development and digitization
processes, facilitates the cooperation of actors, etc. On the
other hand, it also causes unforeseen difficulties, such as
securing the supply of APIs. Hence, PannonPharma had to
expand its manufacturing capacity to meet the needs.
PannonPharma is the only
company so far that offers a new
solution to stop or alleviate the
coronavirus pandemic, where
vaccination is just the first.

The Future of Pharma
When asked about his views on the future of the Pharma
Industry, Mr J. P. Pallos answered, "The Pharma Industry is
depending highly on health (or 'wholeness' as it is defined
in the Hungarian language for the word ‘health') policy.
Nowadays, the main interest is generated from diseases
management. Soon, the policy shall be that of repurposing
pharma industries to health, or more appropriately, to
'Wholeness' management. This is the only option for a
brilliant future."
Word to the Wise
For the budding entrepreneurs and professionals aspiring to
venture into the pharmaceutical industry, J. P. Pallos has
these words of wisdom to share – "One needs to be a good
health strategist, not just a good disease manager only.
Strategy means to vision, see, plan, do, act for 'wholeness',
as it is defined in the Hungarian language for the word
'health'.”
"As far as I can see, this industry is fully regulated,
transparent, and predictable. Any reasonable investment
will profit in time when the demand is realistic, and supply
is structured. And, most importantly, patients are always the
first priority," he added.
A Fortuitous Future Awaits…
Being an R&D company, PannonPharma is looking for
R&D partnerships and investors for market development.
Its vision is growth by magnitudes.
"There are beautiful markets with immense demands, and
we have products to supply the needs. The regulatory to
these markets is a very specific one, and we shall run
clinical trials, preferably in the US. This is the only growth
rate-limiting factor. We intend to out-license some of our
products through investment bankers and investors,"
concluded the astute CEO of PannonPharma – Mr J. P.
Pallos.
PannonPharma Group of
Companies is also a think-tank
that offers simple solutions for
complex problems.

Stay in touch.
Subscribe to Insightscare Get Insightssuccess
Magazine in print, & digital on www.insightscare.com
Check should be drawn in favor of :
INSIGHTS SUCCESS MEDIA TECH LLC

www.insightscare.com
September | 2022 16

www.insightscare.com
September| 2022 17

www.insightscare.com
September | 2022 18

www.insightscare.com
September| 2022 19

Redefining Healthcare Costs
www.insightscare.com
September | 2022 20

ustainable generic drugs are emerging as a game-changer in the
Smedical sector. With rapidly rising healthcare costs, generic
drugs are becoming increasingly important as a cost-effective
and sustainable alternative to expensive branded medicines. Generic
drugs can offer the same therapeutic effects at a fraction of the cost,
making them a viable and affordable option for many patients.
Their effectiveness and affordability make them a practical solution to
the increasing burden of medical costs. Moreover, they are widely
available and often manufactured in large quantities, allowing them to
be widely accessible. This makes them a reliable and cost-effective
option for many people. As the medical sector continues to evolve,
sustainable generic drugs are gaining greater recognition as an
invaluable solution to rising healthcare costs.
Overview of the Medical Sector
The medical sector is growing at a rapid rate, driven by increasing
healthcare costs and a growing population. A growing and aging
population represent a large portion of this demand. In addition, many
countries are experiencing economic growth, which has led to a higher
demand for medical services and products. The medical sector is
expected to grow by more than 5% annually, which is more than double
the average growth rate of the global economy. This sector generates
over $10 trillion in revenue and employs millions of people. As the
medical sector continues to grow and evolve, sustainable generic drugs
are emerging as a game-changer in this industry. With rising healthcare
costs, generic drugs have become increasingly important as a cost-
effective and sustainable alternative to expensive branded medicines.
The Role of
Sustainable
Generic Drugs
in theMEDICAL
SECTOR
www.insightscare.com
September| 2022 21

Advantages of Sustainable Generic Drugs
Generic drugs are cost-effective and sustainable alternatives
to expensive branded medicines. They can offer the same
therapeutic effects at a fraction of the cost, making them a
viable and affordable option for many patients. Their
effectiveness and affordability make them a practical
solution to the increasing burden of medical costs.
Moreover, they are widely available and often
manufactured in large quantities, allowing them to be
widely accessible. This makes them a reliable and cost-
effective option for many people. There are several reasons
why generic drugs are more sustainable than branded
medicines. Firstly, their research and development costs are
lower since they do not require any clinical studies. Due to
this, they are often produced in large quantities and are
widely accessible. Furthermore, generics are made from the
same active ingredients as branded medicines, which
ensures therapeutic effectiveness.
Challenges with Sustainable Generic Drugs
Generic drugs are cost-effective alternatives to expensive
branded medicines. However, they do experience
challenges that can jeopardize their sustainability. For
example, they are often manufactured in small quantities.
This means they are not always widely accessible, and the
amount of supply is often not enough to meet the growing
demand. As a result, there may be a delay in shipping or
availability of the product.
Due to these challenges, the supply of generic drugs may
not always be consistent. This can lead to interruptions in
treatment, which can be problematic for patients who need
a regular supply of these drugs. Another challenge with
generic drugs is the quality of the product. While these
drugs are therapeutically equivalent to branded medicines,
they are not subject to the same rigorous testing as their
branded counterparts. This means that generic drugs may
not meet the same quality and safety standards as branded
medicines, which can be problematic for patients who need
reliable treatment.
Impact of Sustainable Generic Drugs on the Medical
Sector
Sustainable generic drugs are emerging as a game-changer
in the medical sector. With rising healthcare costs, generic
drugs are becoming increasingly important as a cost-
effective and sustainable alternative to expensive branded
medicines. These drugs can offer the same therapeutic
effects at a fraction of the cost, making them a viable and
affordable option for many patients.
Their effectiveness and affordability make them a practical
solution to the increasing burden of medical costs.
Moreover, they are widely available and often
manufactured in large quantities, allowing them to be
widely accessible. This makes them a reliable and cost-
effective option for many people. As the medical sector
continues to grow, sustainable generic drugs are gaining
greater recognition as an invaluable solution to rising
healthcare costs.
Examples of Sustainable Generic Drugs
Generic drugs are cost-effective and sustainable alternatives
to expensive branded medicines. They can offer the same
therapeutic effects at a fraction of the cost, making them a
viable and affordable option for many patients. Their
effectiveness and affordability make them a practical
solution to the increasing burden of medical costs.
Moreover, they are widely available and often
manufactured in large quantities, allowing them to be
widely accessible. This makes them a reliable and cost-
effective option for many people. As the medical sector
continues to evolve, sustainable generic drugs are gaining
greater recognition as an invaluable solution to rising
healthcare costs.
Conclusion
Sustainable generic drugs are emerging as a game-changer
in the medical sector. With rising healthcare costs, these
drugs are becoming increasingly important as a cost-
effective and sustainable alternative to expensive branded
medicines. These drugs can offer the same therapeutic
effects at a fraction of the cost, making them a viable and
affordable option for many patients.
Their effectiveness and affordability make them a practical
solution to the increasing burden of medical costs.
Moreover, they are widely available and often
manufactured in large quantities, allowing them to be
widely accessible. This makes them a reliable and cost-
effective option for many people. As the medical sector
continues to grow, sustainable generic drugs are gaining
greater recognition as an invaluable solution to the rising
healthcare costs.
-Anish Miller
www.insightscare.com
September | 2022 22

By- Graeme Ladds
Current Industry Situation
Throughout the years, pharmaceutical companies, for
their developmental and marketed products, have
continuously worked towards ensuring their
products comply with the varied, numerous, and extensive
legal safety/medical obligations – established and put in
place by various national and international governing
authorities and agencies – to ensure the appropriate level of
vigilance is upheld in accordance with the safety
requirements of each region.
Since the 1960s, the number of adverse reaction reports
received by pharmaceutical companies, Market
Authorisation Holders (MAHs), and regulatory authorities
has risen year after year – a trend which continues to rise to
this day, with the emergence and exponential growth of
markets such as the cosmetics and medical device industries
and the additional legislative changes for all of these areas
bring to the wider pharmaceutical industry, giving reason to
believe this rise will show no sign of slowing any time
soon.
In Europe alone, since the introduction of
numerous pieces of revised and additional
legislation in 2021, as a cumulative result of macro
factors such as Brexit and the Covid-19 pandemic,
adverse reaction reports have increased significantly
– with the number of reports being submitted per year
now at an all-time high.
As a result, this has placed an increased demand within
the drug safety Departments of Companies for adverse
event case processing and analysis duties and has inevitably
led to the subsequent, ever-increasing demand being placed
on employee output and labor; the need for new and
additional staff; the associated cost of hiring and properly
training said staff initially and long term, and the added
pressures placed on ensuring processing timelines are met
in accordance with regulatory requirements.
Moreover, this concern is one already shared by major
industry stakeholders, with notable bodies such as the
World Health Organisation (WHO) and European
Medicines Agency (EMA) highlighting the implementation
Few
Life
Certain
is
www.insightscare.com
September | 2022 24

With a first degree in Biochemistry and Pharmacology, and a Ph.D. focusing on drug metabolism
and Pharmacokine cs, Graeme has worked in the areas of Drug Safety and Medical services for
over 30 years.
Graeme has been working as Head of Global Pharmacovigilance for a mul -na onal innovator
Company and EU QP PV for several of the top ten Pharma Companies, large generic and smaller
innova ve Pharma, and is also the CEO of PharSafer® – a posi on held for the last 19 years.
Furthermore, Graeme is also a member of the DIA; TOPRA; RQA, PIPA and MAPS and has helped
small start-up Companies (Biotech; Advance Therapy; Medical Devices; Biologics; Generics;
Herbal; OTC) in their planning and growth, and has been involved in Company and product
acquisi ons, due diligence ac vi es for product in-licensing and marke ng, and development
strategies with partner and distributor Companies.
Addi onally, Graeme has been involved in many drug-development programs, taking products
from the bench to market in a wide range of therapeu c areas, and also has an addi onal role as
Research & Development Director for products to be developed for global launches.
Graeme Ladds, CEO
About the Author
www.insightscare.com
September| 2022 25

of automation as a key factor in addressing issues with
increasing safety reporting demands and combating the
increasingly inaccurate and poor quality of case reports
respectively.
The Importance of Finding a Solution
In recent years, most notably as a result of the Covid-19
pandemic, the subject of patient safety has excelled to new
heights, with many areas of regulation have been and still
being extensively reviewed and updated, and greater levels
of public interest and involvement leading to large
proportions of both patients and consumers becoming more
aware of the requirements placed on industry organizations
and MAHs. This is paired with industry companies and
MAHs being required to adapt, update and outright change
their company processes to align with any amendments
made to regulation and case volume increases, usually to
scales and within timespans previously otherwise unseen
during this period.
Furthermore, when looking beyond the realm of safety data
capture, reporting, and obtaining follow-up information and
towards the wider pharmacovigilance activities, due to the
activity of case processing is instrumental to ensuring a
company can best address potential new safety information
relating to their product, issues with inaccurate and poor
quality of data processing have a direct, negative impact on
the reliability of safety data analysis duties such as signal
detection, periodic report writing, and benefit-risk
determinations.
Consequently, the ever-rising demand being placed on
safety reporting activities – in line with the aforementioned
factors – has ultimately resulted in an unsustainable strain
being placed upon the wider industry, with the unavoidable
outcome of serious regulatory findings originating from
inaccurate data, incomplete data, and reduced quality of
data reported together with failing compliance becoming
more of an eventuality than a possibility.
The Solution
For these reasons, the need for greater levels of automation
within the pharmaceutical industry and, more specifically,
drug safety has never been greater.
In order for governing and guiding authorities such as the
WHO, FDA, PDMA, and EMA to ensure their goals of
greater levels of ensuring safe and effective products and
patient well-being on a global scale are achieved, the wider
industry will require companies and MAHs to innovate and
streamline processes supported by seeking an automated
leap into the future of data entry and safety reporting and, in
doing so, industry stakeholders will not only see their issues
resulting from the ever-rising demands placed upon the
workforce addressed, but improved to levels not previously
seen before.
Through a greater implementation of automation,
companies will now expect to see the human element of
data entry repositioned towards analysis duties – freeing up
professionals and enabling them to better utilize their skill
sets and apply their knowledge towards finding solutions to
potential safety issues – with manual case data entry set to
become something overseen and driven by automated
processes.
The greater implementation of automation will allow safety
professionals to better concentrate on their analysis duties,
providing greater levels of job fulfillment by removing the
growing pressures felt from increased manual case
processing; removing any repetitious procedures associated
with data entry; eliminating human errors that result
directly from issues with reporting quantities and
timescales, whilst also maximizing the efficiency and
affordability of case processing through superior global
coverage; unprecedented reporting capabilities for both
quantity and timescales; enhanced disaster recovery and
business continuity processes, and reduced costings
typically associated with staffing recruitment and initial and
on-going training.
Furthermore, by addressing issues associated with case
processing and enhancing vigilance over the first phase of
safety reporting processes, improving the efficiency,
consistency, and accuracy of safety data capture and
collection will undoubtedly result in a positive, knock-on
effect on the quality and speed of analysis activities and
promote greater levels of global patient safety for years to
come.
www.insightscare.com
September | 2022 26

Pharmaceutical companies the world over patent the
drugs that are derived from their own research. This
allows them to have a monopoly in the sales of a
product for many years and these companies do not have to
worry about competitors when setting prices. Hence, they
can charge as high a price for products as they want.
But once an initial supplier’s patent, which generally lasts
up to 25 years, expires, other manufacturers of medicines
can also produce these long-standing pharmaceutical
products and sell them at significantly lower prices. These
medicines are called ‘Generics’.
Generics are pharmaceutical drugs that contain the same
active pharmaceutical ingredient as the first supplier’s
proprietary product. Generics are significantly less
expensive, despite their great quality.
A leading manufacturer of high-quality pharmaceuticals,
with a long-standing heritage rooted in pharmacies, is the
Germany-based company that has carved itself a legacy of
care with high-quality pharmaceuticals – STADA
Arzneimittel AG.
STADA is highly regarded in the pharmaceutical sector as a
reliable and trustworthy partner for over 125 years. With its
products, STADA helps protect people and regain a
dignified and able life. With its proven Generics, the
company ensures that everyday health remains affordable.
And for its employees, STADA facilitates an attractive
working environment in which they can develop personally.
STADA focuses on a three-pillar strategy consisting of
generics, speciality pharma, and non-prescription consumer
healthcare products. Worldwide, STADAArzneimittel AG
sells its products in approximately 120 countries. Consumer
Healthcare brands such as Zoflora®, Grippostad®, Snup®,
Aqualor®, Vitaprost® and Nizoral® are among the top
sellers in their respective product categories. In the financial
year 2020, STADA achieved group sales of EUR 3,010.3
million and adjusted earnings before interest, taxes,
depreciation, and amortization (EBITDA) of EUR 713.3
million. As of 31 December 2020, STADA employed
12,301 people worldwide.
“At STADA, we follow our purpose of ‘Caring for people’s
health as a trusted partner’,” remarked the Chairman of the
Executive Board and the trailblazing CEO of STADA
Quality and
responsibility towards
all those who use its
products and services is
a fundamental
component of STADA's
corporate strategy.
Legacy of Care with High-quality Pharmaceuticals
www.insightscare.com
September | 2022 28

st
Since September 1 , 2018, Peter Goldschmidt is
the CEO of STADA Arzneimittel AG. He
strongly pursues the STADA vision, to be the
partner of choice in generics, speciality
medicines and consumer health in Europe and
selected emerging markets, while continuously
outgrowing the industry in terms of growth and
profitability.
Peter Goldschmidt has 30 years' experience and
success in the pharmaceutical industry. He
worked in OTC, Generics and the innovative
Pharma Business in Asia, Europe and the US in
several different leadership functions.
Over the past three years at STADA, Peter
Goldschmidt has led the group on a cultural
journey, implementing a growth mindset culture
based around the common purpose of "Caring
for People's Health as a Trusted Partner". By
ensuring that all of STADA's almost 13,000
employees worldwide truly live the four STADA
values of Agility, Entrepreneurship, Integrity
and One STADA, he has led the group in
consistently delivering above-market sales and
profit growth. As a top-five supplier of both
generic and consumer healthcare
products in Europe, STADA
helps millions of people to
lead healthy, dignified
and fulfilled lives.
Peter Goldschmidt
Interview with Insights Care

roup – Peter Goldschmidt. “In pursuit of this purpose,
G
we are committed to further accelerating the successful
trajectory of our company,” he added.
Caring for People’s Health
As all success stories do, STADAArzneimittel's company
history started with a great idea. In 1895, a group of
pharmacists had a common objective: The standardized
production of medicinal products to ensure an effective and
reasonable provision of healthcare for the many. This was
the beginning of STADA” impressive development.
Today, the company is a leading manufacturer of high-
quality pharmaceuticals. With a long-standing heritage
rooted in pharmacies, the STADA Group is a reliable and
trustworthy partner for more than 125 years.
Purpose: Caring for people’s health as a trusted partner
Vision: To be the partner of choice in generics and
consumer health, while continuously outgrowing the
industry in terms of growth and profitability.
Core Values:
Integrity – “Each and every one of us acts ethically in line
with the company's internal and external standards. Our
actions are led by speaking up and respect.”
Entrepreneurship – “Each and every one of us drives new
ideas and actions, creating future growth and value.”
Agility – “Each and every one of us leads change with
flexibility and decisiveness as part of our ongoing journey
of personal development.”
One STADA – “Each and every one of us acts in the best
interests of the company as a whole rather than our business
unit or function in order to build one successful STADA.”
Quality at STADA
Quality and responsibility towards all those who use its
products and services is a fundamental component of
STADA's corporate strategy. It thereby takes account of the
great significance of quality in product safety in the health
care market. Overall, the company aligns the quality policy
throughout the Group to meet criteria that at least fulfil the
strict legal requirements for pharmaceutical and health care
products.
“Assessing the risks of newly arising, previously unknown
side effects of active ingredients also play an important role
in the quality of pharmaceutical products,” explains the
astute CEO, Peter Goldschmidt. “This risk remains low for
most of our products as only long-standing and researched
active pharmaceutical ingredients are generally used. Of
course, we have nevertheless implemented within our
operations all the standard graduated plan proceedings for
recording or detecting such pharmaceutical product risks
throughout the Group,” he elaborated.
Our strategic priorities and values are the
basis of our entire commitment to
sustainable development in order to lead
sustainable business and growth while
achieving a positive impact on people and
their health, the economy and the
environment. And we bring these to life
every day. For us, caring for people's
health is more than providing support for
prevention and treatment through a
complete range of STADA's quality,
reliable and affordable pharmaceutical
products. It also involves raising
awareness of personal health care and
healthy lifestyles, while supporting public
health care systems. Further, it is our civic
duty to act as responsible citizens - we as
individuals, we as a team and a society.
This is exactly what makes us a partner of
trust and choice when it comes to
people's health.
With its products,
STADA helps
protect people and
regain a dignified
and able life.
www.insightscare.com
September | 2022 30

www.insightscare.com
September | 2022 32

imple sayings often have deep engraved meanings and one of the old
Ssaying is, ‘Health is wealth’.
Understanding that individual could progress best in the good health
conditions, has taken the health sector to new heights of invention. Stormed
with new healthcare inventions with time, one of the most important parts of it
has been taken by technology.
Growing technological involvement in Medicare has led to a reduction of lots
of risks while coming up with better facilities and cures unimaginable a few
decades ago. With the touch of tech Pharmaceutical industries are at immense
benefits.
With ever-changing trends in the industry let us see the amazing developments
in pharmaceutical field topping the list.
The Spark of Artificial Intelligence (AI)
Talking about technological development without AI is nearly unimaginable.
AI is a technology that has crept into almost every field including pharm. The
technology is used in pre-clinical trials of drug designing procedures which
has considerably reduced health hazards involved in it. This entire use of AI
during each step of the process has also considerably reduced the cost of the
procedure benefiting industries.
Being an effective tool for mining data, AI, manages clinical trial databases
while maintaining, organizing, and storing the data securely.
Top Technological
Trends Revamping
the Pharmaceutical
Niche
www.insightscare.com
September| 2022 33

Connecting the Wireless: IoT
Along with AI, IoT or the internet of things has enabled
end-to-end digital integration in the value chain.
Accompanied by Big Data analytics along with cognitive
systems, IoT has created even better chances of
development in the field of medicine and Pharm.
In the pharmaceutical sector, IoT aids in various activities
starting right from the initial stage to the intermediate
process. Used to monitor real-time data, supervise unit
operations, and enhance product efficiency, IoT has made
the tasks of the industry a lot easier. It has become a reliable
technology for the pharmaceutical sector despite being in its
infant stage.
VR, XR, MR: New Dawn in Pharmaceuticals
Virtual Reality (VR), Extended Reality (XR), and Mixed
Reality (MR) are some of the fascinating children of
technology that many restricted to the world of games.
However, with time and the development of these
technologies they have released their potential in various
fields.
These technologies comes to the rescue, as it provides a
structure and allows one to experience the technology or
structure before it is created. Precision is one of the most
important factors while building a structure specifically in
the pharmaceutical industries that require extra care as there
are more chances of hazards during experiments. This real-
life experience helps in the reduction of hazards and gives a
better idea of manufacturing.
Digital Twins: Project for Experiment
Used for testing and monitoring purposes, Digital twins is a
technological boon that is a virtual representation of
systems or objects updated by real-time data. As fascinating
as it sounds the technology helps companies to test products
before actually creating them.
A replica of the planned project is created using this
technique where engineers can identify the potential
process failures before the project is created.
Alert! Patient Update: Digital Pills
Digital pills, as weird as it sounds it is a reality of the day
approved by the FDA, this pill is an amazing contribution
to the field of medicine. The pill is ingested by patients just
like any pill. It allows medical professionals to monitor
their patients ensuring they are following the dosing
schedule recommended. The pills are embedded with
electronic circuits and sensors which are edible and send
messages to operative devices such as smartphones,
patches, or tablets.
This is magic for doctors looking after rebel patients as it
helps them keep tabs on them.
Med for You: Precision Medicine
The belief that every individual is unique and thus requires
treatment accordingly is the underlying principle of
Precision medicine. The initiative involves the study of
biological indicators based on personality traits, genotype,
genetic code, age, gender, etc., and tailoring individual-
specific treatment.
The technology determines the pharmacokinetic and
pharmacodynamics properties of drugs and arrives at a
point of precision for the dosage of drugs.
Cure Over Temporary Relief: Curative Therapies
Being for long time under research curative therapies have
risen to popularity in the field of Medicare. The therapy
provides a time-limited treatment for underlying disease
and symptoms. The driving motive of the therapy is to cure
patients instead of just reducing pain or stress.
These therapies deal with chronic diseases and difficult
conditions.
The therapy includes modification in gene material to help
with the diseases. Chemotherapy could be classified under
curative therapies as it intends to cure cancer patients.
With the time these trends would certainly change further,
be replaced and modified, however, one thing that remains
constant is evolution. We, humans, have evolved with time,
and with us, we have evolved the world surrounding us
which is a continuous process leading us to the future. With
time health and the environment has also raised to the
priority list and I hope it remains so.
As it’s said ‘Health is Wealth.’
-Anish Miller
www.insightscare.com
September | 2022 34